Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532671 | 0.91 | PPARD (0.54) | FFAR4FFAR1PTGER4PTGER3PTGER1 | |
| SCHEMBL2534776 | 0.90 | FFAR1 (0.56) | FFAR4FFAR1PTGER4PTGER3PTGER1 | |
| SCHEMBL2536628 | 0.89 | FFAR1 (0.53) | FFAR4FFAR1PTGER4PTGER3PTGER1 | |
| SCHEMBL2538764 | 0.88 | FFAR1 (0.55) | FFAR4FFAR1PTGER4PTGER3PTGER1 | |
| SCHEMBL2537526 | 0.87 | FFAR1 (0.58) | FFAR4FFAR1PTGER4PTGER3PTGER1 | |
| SCHEMBL2532590 | 0.87 | FFAR1 (0.58) | FFAR4FFAR1PTGER4PTGER3PTGER1 | |
| SCHEMBL2536454 | 0.85 | FFAR1 (0.52) | FFAR4FFAR1PTGER4PTGER3PTGER1 | |
| SCHEMBL2537299 | 0.85 | FFAR4 (0.47) | FFAR4FFAR1PTGER4PTGER3PTGER1 | |
| SCHEMBL2539633 | 0.84 | FFAR4 (0.52) | FFAR4FFAR1PTGER4PTGER3PTGER1 | |
| SCHEMBL2535066 | 0.83 | FFAR4 (0.49) | FFAR4FFAR1PTGER4PTGER3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| EP-2080751-A1 | CARBOXYLIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20080275116-A1 | Carboxilic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275116-A1 | Carboxilic acid derivatives | SERPINE1, CTRL, SERPINC1 | FFAR4 2537/4885FFAR1 710/4885PTGER4 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.